{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"55","upperLimit":"172","value":"104"},{"groupId":"OG001","lowerLimit":"28","upperLimit":"961","value":"446.25"},{"groupId":"OG002","lowerLimit":"54","upperLimit":"1248","value":"718"},{"groupId":"OG003","lowerLimit":"60","upperLimit":"853","value":"331.25"},{"groupId":"OG004","lowerLimit":"6","upperLimit":"874","value":"263.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"30"}],"units":"Participants"}],"description":"Phase II - To determine the duration of response achieved as in secondary endpoint one. The duration of response is measured from the time measurement criteria are met for major or complete platelet response (which ever is first recorded) until the first date that disease progression defined by the bone marrow response outlined above, progression/relapse following a CR, marrow CR or PR, or progressions/relapse following hematological improvement (HI) as outlined above.","dispersionType":"Full Range","groups":[{"description":"Phase 1, Level 1: Ruxolitinib 5 mg twice daily","id":"OG000","title":"Phase 1, Level 1: Ruxolitinib 10 mg"},{"description":"Phase 1, Level 2: Ruxolitinib 10 mg twice daily","id":"OG001","title":"Phase 1, Level 2: Ruxolitinib 20 mg"},{"description":"Phase 1 Level 3: Ruxolitinib 15 mg twice daily","id":"OG002","title":"Phase 1, Level 3: Ruxolitinib 30 mg"},{"description":"Phase 1, Level 4: Ruxolitinib 20 mg twice daily","id":"OG003","title":"Phase 1, Level 4: Ruxolitinib 40 mg"},{"description":"Treatment at Maximum Tolerated Dose (MTD).","id":"OG004","title":"Maximum Tolerated Dose - Ruxolitinib"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"3.5 years","title":"Duration of Response in Days","type":"SECONDARY","unitOfMeasure":"days"}